sorafenib

Targeted drugs in the treatment of renal cell carcinoma : sorafenib

肾细胞癌靶向治疗进展&索拉非尼

Sorafenib is currently approved in the United States and other countries for treatment of advanced renal cell carcinoma .

当前索拉非尼在美国和其他国家被批准用来治疗晚期肾细胞癌。

In the latter scenario , sorafenib should also constitute the control arm of these trials .

在近来的方案中，索拉菲尼将成为这些实验中的控制臂。

Consequently , sorafenib will become the standard of care in advanced cases , and the control arm for future trials .

同时，索拉菲尼将会是早期病例的标准治疗方法和未来试验的对照药。

Investigators and cooperative groups are currently evaluating sorafenib in various breast cancer treatment settings , according to Bayer .

据拜耳消息，研究人员和投资方目前正在对索拉非尼应用于各种乳腺癌治疗情况进行评测。

The study was stopped prematurely when a planned interim analysis showed sorafenib 's significant superiority over placebo .

根据计划，当中期分析显示索拉非尼的效果明显优于安慰剂时，研究会过早的中止。

Sorafenib : pharmacology and clinical studies

索拉非尼的药理及临床研究

Treatment duration was a median of23 weeks in the sorafenib group and19 weeks in the placebo group .

治疗时间中位数在索拉非尼组为23周，在安慰剂组为19周。

We are currently doing a multi-centre trial looking to see if the addition of sorafenib in adjuvant therapy will be beneficial .

目前，我们正在进行一项多中心临床试验，研究在辅助治疗方案中添加索拉非尼是否有效。

The Heidelberg researchers have shown that brain cells which are driven to permanent abnormal cell division by a defective BRAF gene slowed down growth after treatment with kinase inhibitor sorafenib .

海德堡的研究人员已通过试验证实由于BRAF基因缺陷而被导致永久性异常分裂的大脑细胞，经激酶抑制剂索拉菲尼处理后，生长速度明显降低。